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INTRODUCTION 
 Preeclampsia is a human pregnancy specific, multi system disorder that 
is  characterized by hypertension and proteinuria1. Inspite of intensive effort to 
identify the pathophysiological mechanism neither a specific cause nor a 
pathogenesis has been identified.  
Roes, EM et al.hypothesised that endothelial dysfunction plays a major 
role in preeclampsia2. 
 Carl A. Hubel reviewed the role of oxidative stress in vascular 
endothelial cell damage and also recorded increased level of lipid peroxidation 
products in preeclampsia3. 
 Atamer Y et al. reported that the plasma antioxidant activity in 
preeclampsia is defective, and could be the causative factor that is responsible 
for endothelial damage4. 
 Gutteridge JMC et al. reported that Ceruloplasmin is the major plasma 
antioxidant and its activity is found to decrease in preeclampsia5. The increased 
lipid peroxidation along with decreased ceruloplasmin activity may play a role 
in pathogenesis of preeclampsia.6 
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The present study was carried out to determine the level of plasma, 
malondialdehyde [MDA] as a marker of lipidperoxidation and ceruloplasmin as 
an antioxidant against lipid peroxidation. By performing the above parameters 
in preeclampsia the antioxidant status and oxidative stress were studied. 
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REVIEW OF LITERATURE 
 Southern, PA et al. reviewed the involvement of free radicals and other 
reactive species in the pathogenesis of different human diseases7. 
 Seis. H. in 1991 defined oxidative stress as a disturbance in prooxidant - 
antioxidant balance in favour of the former leading to potential tissue damage8. 
 Carl. A. Hubel reported that the vascular endothelial changes in 
preeclampsia result from oxidative stress. 
 Roberts, JM et al. proposed that the products of feto placental unit enter 
the circulation and then initiate maternal patho physiological changes9. 
 Walsh, SC et al. reported that lipid peroxidation products primarily as 
thiobarbituric acid reactive substances (which include malondialdehyde) are 
increased in plasma of women with preeclampsia10. 
 Lipid hydroperoxides regulate enzymes and redox sensitive genes11. 
However uncontrolled lipid peroxidation can result in cellular dysfunction and 
damage. 
 Under normal conditions antioxidant defence system in the body inhibits 
lipid peroxidation by interfering with the chain reaction of peroxidation. 
 The major intracellular antioxidants are catalase, superoxide dismutase, 
and glutathione peroxidase. But the extra cellular fluid plasma contains little or 
no catalase activity and only low activities of superoxide dismutase and 
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glutathione peroxidase. Transferrin and ceruloplasmin are shown to be major 
plasma antioxidants12. 
HYPERTENSIVE DISORDERS COMPLICATING 
PREGNANCY 
 The term hypertensive disorders complicating pregnancy includes a 
heterogenous collection of hypertensive disorders which are peculiar to 
pregnancy. Nearly 18% of maternal deaths are related to these hypertensive  
disorders. 
 The working group of National High Blood Pressure Education 
programme proposed a classification for the hypertensive disorders 
complicating pregnancy13. 
 There are five types of hypertensive disorders complicating pregnancy. 
 They are 
 1) Gestational hypertension 
 2) Preeclampsia 
 3) Eclampsia 
 4) Preeclampsia super imposed on chronic hypertension 
 5) Chronic hypertension 
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DIAGNOSIS OF HYPERTENSIVE DISORDERS COMPLICATING  
PREGNANCY 
 The criteria for diagnosing hypertensive disorders complicating 
pregnancy are outlined by National High Blood Pressure Education Programme 
Working group13. 
1) Gestational Hypertension 
 BP ≥ 140 /90 mmHg for the first time during pregnancy 
 No proteinuria 
 BP returns to normal after 12 weeks of postpartum 
2) Preeclampsia 
 Minimum criteria for diagnosing preeclampsia are 
 1) BP ≥ 140 / 90 mmHg after 20 weeks of gestation. 
 2) Proteinuria ≥ 300 mg / 24 hours or > 1 + by dipstick method. 
 Presence of the following signs or symptoms increased the certainty of 
preeclampsia 
  BP ≥ 160 / 110 mm Hg 
 Proteinuria 2.0 g / 24 hours or > 2 + by dipstick method 
 S. creatinine > 1.2 mg / dl unless known to be previously elevated. 
 Microangiopathic haemolysis as evidenced by increased LDH. 
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 Elevated Alanine & Aspartate  transaminase. 
 Persistent headache or other cerebral or visual disturbance 
 Persistent epigastric pain 
Eclampsia 
 Occurrence of seizures that cannot be attributed to any other cause in 
women with preeclampsia. 
Preeclampsia Superimposed upon Chronic Hypertension 
 New onset of proteinuria ≥  300 mg/ 24 hrs in hypertensive women but 
no proteinuria before 20 weeks gestation. 
 A sudden increase in proteinuria or blood pressure or platlet count  
< 100,000 / mm3 in women with hypertension and proteinuria before 20 weeks 
of gestation.  
Chronic Hypertension 
 BP ≥ 140 / 90 mmHg before pregnancy or diagnosed before 20 weeks 
gestation or hypertension first diagnosed after 20 weeks gestation and 
persistent after 12 weeks  postpartum. 
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PRE-ECLAMPSIA 
 Preeclampsia is a pregnancy specific syndrome of reduced organ 
perfusion secondary to vasospasm and endothelial activation. 
Incidence & Risk Factors 
 The incidence varies from 8-10 percent in Indian population. 
1. It occurs chiefly in primigravidae14. 
2. It is more common in multiple pregnancy, hydramnios and vesicular 
moles. 
3. It may occur in association with maternal disease like diabetes mellitus, 
hypertension and renal disorder14. 
Diagnosis 
 The minimum criteria for diagnosing preeclampsia are hypertension and 
proteinuria15. 
 Proteinuria is described as the presence of 300mg or more of urinary 
protein per 24 hours or persistent 30 mg / dL (1 + dipstick) in random urinary 
sample. 
 Hypertension is diagnosed when blood pressure is 140/90 mmHg or 
more using Karotkoffs phase V to define diastolic pressure16. 
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Signs & Symptoms 
 Apart from proteinuria and hypertension mild preeclampisa have no 
other signs or symptoms. In severe cases symptoms of headache, restlessness, 
vomiting, epigastric pain, and visual disturbance may be present17. 
 Abnormal biochemical findings in renal, hepatic, hematological 
functions may also be present in preeclampsia. 
 The abnormal biochemical findings include 
a) Platelet count < 100, 000 / mm3  
b) Elevated serum uric acid more than 5.9 mg / dl. 
PATHOLOGY 
 Most of the pathological consequences are due to vasospasm that leads 
to decreased end organ perfusion. Preeclampsia adversely affects the mother 
and fetus. 
Changes in the maternal organs and functions consequent to preeclampsia 
1) Cardiovascular Changes 
 Benedetti and their associates reported high systemic vascular 
resistance, hyperdynamic ventricular function, and reduced blood volume in 
preeclampsia18. 
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2) Hematological Changes 
 Thrombocytopenia is the most common finding in preeclampsia19. It is 
likely to result from platelet activation and consumption. Thrombocytopenia is 
some time accompanied by erythrocyte destruction. This destruction is 
evidenced by the presence of reticulocytosis. 
Endocrine Changes 
 In preeclampsia there is sodium retention and hypertension. Both of 
these factors lead to decrease secretion of renin by juxtaglomerular apparatus. 
Renin is necessary for the conversion of angiotensinogen to angiotensin I. 
Angiotensin I is then converted to Angiotensin II by Angiotensin converting 
enzyme.  Angiotensin II stimulates aldosterone secretion. Due to decrease renin 
secretion the aldosterone secretion also impaired20. 
Fluid Changes 
 In preeclampsia renal endothelial injury leads to proteinuria. 
Renal Changes 
 Glomeruli are enlarged with glomerular capillary endothelial swelling. 
The swollen endothelial cells block the capillary lumen21. 
 Renal perfusion and GFR are reduced. Preeclampsia is associated with 
increased concentration of serum creatinine and uric acid and diminished 
urinary calcium excretion22. 
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Liver 
 Due to numerous scattered areas of subscapular haemorrhage its 
appearance is mottled. Increased liver enzymes are due to periportal 
haemorrhagic necrosis in the periphery of liver lobules23. 
Placenta 
 Placenta plays a major role in maternal endothelial dysfunction in 
preeclampsia24. This is evidenced by the disappearance or remission of 
preeclampsia after termination of pregnancy. The genesis of preeclampsia is 
clearly related to deficient trophoblast invasion and failure of uterine artery 
remodeling25. Preeclampsia placentas show abnormal expression of integrin 
molecules.  Integrin molecules regulate cell to cell and cell to matrix 
interactions. As a result trophoblastic invasion is inhibited and spiral artery 
remodeling is often limited to the decidual portions. So the myometrial 
segments do not widen and remain contractile. This defective spiral artery 
remodeling results in reduced utero placental perfusion and foci of placental 
hypoxia or ischemia. 
 Numerous markers of oxidative stress are altered in placenta of 
preeclampsia. 
 Anatomically the placenta of preeclampsia shows increased syncytial 
knots, areas of infarcts26. Microscopically there is a loss of syncytium, 
proliferation of cytotrophoblast, villous necrosis, and fibrinoid degeneration of 
maternal decidual arteries. 
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PATHOPHYSIOLOGY 
 Vasospasm: Vasospasm is basic to pathophysiology of preeclampsia. 
Vasoconstriction accounts for the development of arterial hypertension27. 
Increased pressure response  
 There is increased sodium retention in preeclampsia. The shift of sodium 
into arterial wall increases the sensitivity of vascular endothelium to circulating 
vasopressors28. 
Prostaglandins 
 Thromboxane A2 is increased; prostacylin and prostaglandin E2 are 
decreased in preeclampsia, resulting in vasoconstriction29. 
Vascular Endothelial Growth Factor (VEGF) 
 It is a glycoprotein and selectively mitogenic to vascular endothelium. It 
is important for vasculogenesis and micro vascular permeability. VEGF has 
been reported to increase in preeclampsia. Increased VEGF may represent a 
compensatory mechanism attempting to restore utero placental blood flow to 
normal30. 
Oxidative Stress 
 Lorentzen, B. et. al. reported that lipid alteration may promote oxidative 
stress in preeclampsia31. 
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 The mean TGL and FFA concentrations undergo near doubling in 
women with preeclampsia relative to normal pregnancy. The plasma TGL level 
rises above 400mg / dl32. This hyper triglyceridemia of preeclampsia is also 
accompanied by increased prevalence of smaller and denser LDL particles and 
decreased HDL cholesterol. Smaller denser particles of LDL are more 
atherogenic. Due to their small size, these particles more readily infiltrate into 
arterial tissue, the presumed site of LDL oxidation. Compared to large particles 
of LDL, the small dense LDL particles are more susceptible to oxidation33.  
 In trophoblasts and macrophages of the normal placenta, scavenger 
receptor activity greatly exceeds native LDL receptor activity. LDL might be 
prone to oxidation during its relatively slow travel through the intervillous 
space in direct contact with trophoblast cells34.  The smaller and denser LDL 
particles formed during pregnancy are increasingly susceptible to oxidation. 
The stable peroxidation metabolites produced during placental oxidative stress 
enter the maternal circulation and produce widespread endothelial damage and 
dysfunction35.  
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FREE RADICAL 
STRUCTURE OF ATOM 
 An atom is a simplest unit of an element. It is made up of a central 
nucleus which contains protons and neutrons. The protons are positively 
charged and the neutrons are uncharged. The nucleus is surrounded by 
electrons. The electrons are negatively charged. Stable compounds have even 
number of electrons paired in outer most orbital with opposite spin. Barrywell 
defined free radical as “any species capable of independent existence that 
contain one or more  unpaired electron. An unpaired electron is one that 
occupies an atomic or a molecular orbital without a pair36.  
Free radicals include oxygen centered radicals, carbon centered radicals, 
nitrogen centered radicals and transition metals. 
Role of Free Radicals in Lipid Peroxidation 
 In lipid peroxidation oxygen centered radicals initiate and propagate the 
chain reaction of peroxidation. The transition metals decompose hydro 
peroxides, the end product of lipid peroxidation. 
Oxygen Centered radicals 
 The oxygen centered radicals include  
 1. Hydroxyl radicals •OH  
 2. Peroxyl •2RO  
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 3. Alkoxyl •RO  
 4. Super oxide  −•2O  
 Among the oxygen centered radicals OH• radicals initiate lipid 
peroxidation37, alkoxyl (RO•) and peroxyl (ROO•) radicals propagate the chain 
reaction. 
HYDROXYL RADICALS :  
Among the oxygen centered radicals, hydroxyl radicals are more reactive. 
Formation of OH•  radicals 
1. Absorption of radiation energy: Ionizing radiation produced by 
ultraviolet and X rays can hydrolyze water into hydroxyl ions38. 
2. During oxidative phosphorylation oxygen undergoes reduction to 
produce water. Partial reduction of oxygen leads to the formation of 
oxygen free radicals including hydroxyl radical. 
3. Fenton reaction: Ferrous ion has 4 unpaired electron in 3’d’ orbital.  
These ions interact with hydrogen peroxide and form hydroxyl radical. 
 Fe2+ + H2O2 → Fe3+ + OH• +OH–  39 
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ROLE OF TRANSITION METALS IN LIPID PEROXIDATION 
 Many metals in the Ist row of’d’ block in the periodic table contain 
unpaired electron and can qualify as free radical. 
 Iron and copper are the two metals which take part in lipid peroxidation. 
Iron In Lipid Peroxidation 
 Iron has 2 common oxidation numbers. Iron atom has 4 unpaired 
electrons. Ferrous iron has 4 unpaired, and Ferric iron has 5 unpaired electrons. 
The electron configuration of iron radicals   
   3d    4s  
Iron Atom            Ar ↑↓ ↑ ↑ ↑ ↑   4 unpaired electron 
         
Iron (II) ion          Ar ↑↓ ↑ ↑ ↑ ↑   4 unpaired electron 
        Fe2+         
         
Iron (III) ion Fe3+ Ar ↑ ↑ ↑ ↑ ↑   5 unpaired electron 
 
 Iron bound to phosphate esters, carbohydrates, membrane lipids, can 
decompose lipid peroxides  to form alkoxyl and peroxyl radicals. 
 Role of iron in peroxide decomposition 
 Lipid peroxides are usually stable. They decompose in the presence of 
metal ions40. 
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 Ferrous ion combines with lipid peroxides and produce alkoxyl radical. 
 ROOH  +  Fe2+  →  Fe3+  + RO• 
Alkoxyl radical can abstract hydrogen atom from a second molecule of PUFA 
and  forms  peroxyl  and  carbon  centered radical . 
                       RO• + RH  →  ROH + R• 
ROOH  +  RO•  →  ROO•  + ROH 
 Ferric ions combine with lipid hydro peroxides and decompose them to 
peroxyl radicals40. 
 ROOH + Fe3+  → ROO•  +  H+ + Fe2+ 
Role of Copper in decomposition of lipidperoxides 
 Copper has two oxidation numbers Cu+ (cuprous) Cu2+ (cupric). Copper 
atom has one unpaired electron, and cuprous ion has one unpaired electron. 
The electron configurations are as follows. 
   3d    4s  
Copper Atom        Ar ↑↓ ↑↓ ↑↓ ↑↓ ↑↓  ↑ One unpaired electron 
         
Copper (I) ion       Ar ↑↓ ↑↓ ↑↓ ↑↓ ↑↓   Not a radical 
         
Copper (II) ion    Ar ↑↓ ↑↓ ↑↓ ↑↓ ↑   One unpaired electron 
 They act mainly on preformed lipid hydro peroxides41. 
 Cupric ion decomposes the peroxides to peroxyl radical. 
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 ROOH + Cu2+   →  Cu+  +  RO2•  + H+ 
 Cuprous ion decomposes peroxides to alkoxyl radical. 
 ROOH  + Cu+   →  RO•   +  Cu2+  + OH– 
 Both the peroxyl and alkoxyl radicals promote the propagation of lipid 
peroxidation. 
LIPID PEROXIDATION 
 Lipid peroxidation is defined as oxidative deterioration of lipids. Poly 
unsaturated fatty acids (PUFA) are more susceptible to lipid peroxidation. This 
reaction proceeds in a self amplifying manner. So it is called chain reaction. 
This chain reaction occurs in three stages. They are (1) Initiation  
(2) Propagation   (3) Termination. 
INITIATION 
 Any radical that is capable of abstracting a hydrogen atom from a 
methylene group of PUFA can initiate peroxidation. More frequently OH• 
radical initiate lipid peroxidation by abstracting H• 37from methylene group. 
This leaves an unpaired electron on the methylene carbon. So a carbon centered 
radical [R•] is generated. 
 
  RH                     R• 
 
OH• H2O 
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PROPOGATION 
 The carbon centered radical can undergo various reactions. They are: 
1. Two of the carbon centered radicals collide within the membrane and 
they cross link adjacent fatty acid side chains42. 
2. Under aerobic condition the carbon centered radical combines with 
oxygen and gives peroxyl  (ROO•) radical. 
 R•  +  O2  →  ROO• 
 This peroxyl  radical attacks adjacent fatty acid side chain to form 
carbon centered radical 
 ROO•  + RH  →  ROOH  + R• 
 The carbon radical formed can react with oxygen to form another 
peroxyl radical. In this way the chain reaction of lipid peroxidation continues42. 
 The peroxyl radical combines with the hydrogen atom that it abstracts 
from PUFA to give a lipid hydroperoxide. 
 Peroxyl radical can attack a double bond in the same side chain of 
PUFA to produce cyclic peroxide and cyclic endoperoxides. Hydrolysis of 
cyclic endoperoxides produce Malondialdehyde43. 
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Reproduced from ‘Free Radicals in Biology and Medicine’ by Barry 
Halliwell and John M.c. Gutteridge44. 
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BIOLOGICAL EFFECTS OF THE PRODUCTS OF LIPID 
PEROXIDATION: 
 During the propagation of lipid peroxidation the peroxyl and alkoxyl 
radicals are generated. The end product lipid hydroperoxide undergoes 
decomposition and produces malondialdehyde, hydroxy nonenals (HNE) and 
isoprostanes45. These products serve as a marker for lipid peroxidation and are 
implicated in damages caused to various cellular structure and function. 
EFFECTS OF MALONDIALDEHYDE 
 MDA attacks various amino acid residues of protein and form inter and 
intra molecular cross links. MDA reacts with guanine of DNA and can 
introduce mutagenic lesions46.  
HYDROXY NONENAL [ HNE ] 
 HNE generated in vivo forms adduct with protein and DNA. HNE 
inhibits cell growth and it has chemotactic activity. It can modify lipoproteins 
and promote atherosclerosis47. 
EFFECTS OF ALKOXYL AND PEROXYL RADICALS 
 The peroxyl and alkoxyl radicals of lipid peroxidation can cause severe 
damage to membrane proteins. These radicals can damage specific amino acid 
residue present in various proteins48. 
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Proteins contain histidine residues at their metal binding site. 
Modification of these residues produce signal sequences that are recognized by 
proteases. The proteases degrade such proteins49. 
 Cell membranes contain surface receptors for hormones and cytokines. 
The alkoxyl and peroxyl radicals damage the protein component of these 
receptors. 
 Enzymes like glucose-6-phosphatase, glycerol-3-phosphate acyl 
transferase are inactivated by alkoxyl and peroxyl radicals. 
 Various protein channels and pumps necessary to maintain intracellular 
ion balance are damaged by lipid peroxides50. The Ca2+ ATpase of endoplasmic 
reticulum, Na,K+- ATpase, and K+ channels can also be damaged during lipid 
peroxidation. 
 As lipid peroxidation decreases the membrane fluidity and increases the 
permeability of the bilayer, substances that usually can not cross the membrane 
enter the cells and destroy them. Rupture of lysosomal membrane can also 
results in the release of hydrolytic enzymes into the cell. These enzymes 
damage the other intracellular structures. 
EFFECTS OF ISOPROSTANES 
 One of the isoprostane 8-epi.PGF2α is a potent vasoconstrictor and 
platelet aggregator51. 
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MALONDIALDEHYDE 
 Malondialdehyde [MDA] is one of the low molecular weight end 
products of lipid hydroperoxide decomposition and most often measured as an 
index of lipid peroxidation. MDA can also be formed during eicosanoid 
metabolism.  
STRUCTURE OF MDA 
 O = CH – CH2 – CH = 0 
MDA exists in various form depending on pH52.  At physiologic pH it exists 
as the enolate anion. In acidic pH it exists as undissociated enol and keto forms. Like 
most aldehydes MDA in aqueous solution is prone to aldol condensation which 
produce dimmers, trimers and large polymers. 
MDA is rapidly metabolized in mammalian tissue. Aldehyde 
dehydrogenase oxidize MDA to malonic acid.  Malonic acid is decorboxylated 
to acetaldehyde. Acetaldehyde is oxidized to acetate by aldehyde 
dehydrogenase 
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.Various forms of MDA in aqueous solution 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Reproduced from ‘Free Radicals in Biology and Medicine’ by Barry 
Halliwell and John M.c. Gutteridge.53 
Dimer 
Trimer 
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ANTI OXIDANT DEFENCE SYSTEM 
 Halliwell et al., defined antioxidant as "any substance when present at 
low concentrations compared with those of an oxidizable substrate significantly 
delays or prevents oxidation of substrate".54 
 The major intracellular antioxidants are catalase, superoxide dismutase 
and glutathione. The plasma antioxidants are Vitamin C, Vitamin E, and 
Ceruloplasmin.  
Antioxidants effective against lipid per oxidations : 
 The hydroxyl radicals are effectively scavenged by glutathione. The 
peroxyl and alkoxyl radicals are detoxified by vitamin C and E. Ceruloplasmin 
prevents copper and iron induced decomposition of lipid hydroperoxides. 
Antioxidant role of Glutathione 
 Glutathione is γ glutamyl cysteinglycine. It is present in reduced state 
where glutamate is linked to cystein and glycine. 
 Glutathione detoxifies hydroxyl radicals. This reaction is catalyzed by 
selenium containing glutathione peroxidase. During this reaction glutathione is 
oxidized to glutathione disulfide (GS-SG)55. 
 The cell regenerates reduced glutathione by a reaction catalyzed by 
glutathione reductase. This enzyme utilizes NADPH as a source for electrons. 
The NADPH is generated from oxidative phase of HMP shunt. 
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Mechanism of hydroxyl radical scavenging by glutathione 
  
 NADP  GSH          OHo 
 
glutathione        Glutathione Peroxidase 
 reductase    
 
 NADPH+  H+     H2O 
 
ASCORBIC ACID 
 Ascorbic acid (Vitamin C) is a water soluble vitamin. It is the enolic 
form of an α ketolactone. The molecular structure contains two ionizable OH 
group.  Its antioxidant properties are due to its ability to donate electrons from 
the OH group56.  It is an effective scavenger of many free radicals mainly 
peroxyl radicals. During this process it losses two electrons and is converted 
first to ascorbyl radical and then to dehydroascorbate57. It protects lipoproteins 
from peroxidation by scavenging peroxyl radicals before they propagate lipid 
peroxidation. 
 
 
 
GS - SG
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  OH – CH2 OH          OH – CH2OH 
             |                      | 
             CH            CH 
         NAD       NADH +H+    
    O          O         O 
 
      OH     OH                 O     O 
         Ascorbic Acid    2H+  Dehydroascorbic acid 
 
 The enzyme dehydroascorbate reductase converts dehydroascorbic acid 
to ascorbic acid using NADH as reductant. 
 Apart from peroxyl radicals vitamin C scavenges hydroxyl and super 
oxide radicals. vitamin C plays a major role in regenerating active form of 
vitamin E58. 
Vitamin E 
 Vitamin E is a lipid soluble vitamin. It is the most powerful inhibitor of 
propagation of lipid peroxidation. Vitamin E has hydroxylated aromatic ring 
(chromanol ring) and isoprenoid side chain. The chromanol ring contains a 
phenolic hydroxyl group. Vitamin E is highly lipophilic and resides almost 
exclusively in cell membrane. In the lipid bilayer the chromanol ring lies at the 
surface, and the side chain is inserted into the bilayer59. 
O
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 During the propagation stage of lipid peroxidation the peroxyl radicals 
attack the second molecule of PUFA and produce carbon centred radical.
 The carbon centred radical under aerobic condition combines with 
oxygen and again produce peroxyl radical. This peroxyl radical propagates the 
chain reaction of lipid peroxidation. 
 Vitamin E prevents the propagation of lipid peroxidation induced by 
peroxyl radical. The hydroxyl group present on the chromanol ring of Vitamin 
E reacts with peroxyl radical, to form the corresponding hydroperoxide and 
tocopheroxyl radical (Vitamin E - O•)60. In this way Vitamin E acts as a chain 
breaking antioxidant preventing further autooxidation of lipids. 
 In the absence of Vitamin E 
 ROO• + RH  →  ROOH + R• 
  R•  + O2  → ROO•  thus more free radicals are produced. 
In the presence of Vitamin E  
  ROO• + Vit E  – OH  → ROOH + Vit  E – O• 
here tocopheroxyl radical is produced60. 
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ANTIOXIDANT NET WORK 
 The tocopheroxyl radical Vit E – O• is not the active form of Vitamin E. 
Vitamin E is converted to tocopheroxyl radical while scavenging peroxyl 
radicals. When tocopheroxyl radical emerges from lipid bilayer it accepts an 
electron from ascorbic acid and returns to its reduced state Vitamin E. During 
this process ascorbic acid loses one electron and becomes ascorbyl radical. In 
this way Vitamin E necessary for free radical scavenging is continuously 
regenerated61. 
Tocopherol 
 
 
 
 
 
 
 
Tocopheroxyl radical 
Oxidation of Vitamin E by lipid radicals and reduction by Vitamin C. 
Reproduced from ‘Modern Nutrition in Health and Disease’62 by Maurice E 
Shills.  
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CERULOPLASMIN 
BIOCHEMISTRY 
It is an α 2 globulin  which has single polypeptide chain with 1046 
amino acids and three glucosamine linked oligosaccharide side chain. The 
molecular mass is about 132 KD. Each molecule contains 6-8 Copper atoms  
most of which are tightly bound. 
SYNTHESIS 
It is synthesized primarily in hepatic parenchymal cells. The peptide 
chain is formed first then Copper is added63.  The CHO side chains are 
subsequently added in the endoplasmic reticulum.  Copper appears to be 
essential for the normal folding of polypeptide chain and possibly for normal 
CHO side chain attachment.  
REMOVAL 
Sialic acid is  slowly removed from circulating ceruloplasmin by tissue 
and plasma neuroaminidase, resulting in exposure of the terminal galactose 
residue on carbohydrate side chain.  Once a critical number of galactose 
residues are exposed the protein is rapidly removed by galactose receptors of 
hepatic parenchymal cell and catabolized. 
Function 
It can function either as an antioxidant or antioxidant depending on the 
other factors such as the presence of free ferric ions and ferritin binding site. 
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Acting as ferroxidase, ceruloplasmin is vitally important  in regulating the ionic 
state of iron in particular oxidizing Fe3+ to Fe2+ .  It thus permits the 
incorporation of iron into transferrin without the formation of toxic iron 
products64. 
Under physiological condition ceruloplasmin is also important in the 
control of membrane lipid oxidation – probably by direct oxidation of cations 
thus preventing their catalysis of lipid peroxidation. 
Ceruloplasmin is also important in the control of membrane lipid 
oxidation – probably by direct oxidation of cations thus preventing their 
catalysis of lipid peroxidation. 
Ceruloplasmin inhibits the decomposition of lipid hydroperoxides 
exhibited by copper ions by binding to the metal. 
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AIM OF THE STUDY  
The aim of the study was to evaluate the role of oxidative stress in the 
pathogenesis of preeclampsia by measuring the plasma MDA and CP as a 
markers for oxidative stress in preeclampsia.  The study includes the 
measurement of ceruloplasmin activity to assess the decreased antioxidant 
capacity in preeclampsia.  The relationship between MDA and CP were 
statistically analysed to assess the oxidative stress in preeclampsia. 
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MATERIALS & METHODS 
STUDY DESIGN 
 The study was conducted after obtaining approval from ethical 
committee of Stanley Medical College. 
The study population includes three different groups. 
Group 1 
 Consists 30 non pregnant, normotensive females.  
           Age 21 – 32 
Parities P0,P1,P2. 
Group 2 
 Consists 30 normotensive pregnancies. 
Age group between 21 - 32, Gestational age 20 - 35 weeks and obstetric 
score G1 P0, G2 P1, G3 P2.   
Group 3 
 Consists 30 preeclampsic pregnancies.  
Age group between 21 - 32, Gestational age 20 - 35 weeks and obstetric 
score G1 P0, G2 P1, G3 P2.   
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Group 1 served as control for group 2. 
Group 2 served as control for group 3. 
 Normal pregnant and preeclampsic women were chosen from 
G.R.S.R.M. lying in hospital. They were included into the study after obtaining 
informed consent. Healthy unpregnant subjects were chosen from general 
population and after obtaining informed consent they were included into the 
study. 
Diagnosis of Preeclampsia 
 The diagnosis of preeclampsia was made on the basis of elevated blood 
pressure and proteinuria. 
Blood Pressure 
 Hypertension was diagnosed when blood pressure was > 140 / 90 
mmHg, in a pregnant woman after 20 weeks of gestation. The Korotkoffs 
Phase V was used to determine diastolic blood pressure. 
Proteinuria 
 The degree of proteinuria was detected by dipstick method. 
 A dipstick reading >1+ in a random sample was considered as 
proteinuria. 
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Case Selection 
 Inclusion Criteria: Group 1 : 
 Non pregnant, normotensive women with age between 21 - 32 years, 
without hyper tension and proteinuria. 
Group 2 
 Pregnant women with age group 21 - 32 years without hypertension and 
proteinuria with gestational age 20 - 35 weeks. 
Group 3 
 Proven cases of preeclampsia with age group of 21 - 32 years with 
gestational age of 20 - 35 weeks. 
Exclusion Criteria 
1. History of hypertension, diabetes mellitus, tuberculosis, cardio vascular 
disorder. 
2. Bad obstetric history. 
3. Primary lipid disorder. 
4. Any infection. 
5. Anemia. 
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Sample Collection 
 After obtaining written and informed consent urine and blood samples 
were collected. 
Collection of Blood Samples 
 5 ml of blood was collected from each subject participating in this study. 
The samples were collected in a EDTA tubes. The tubes were allowed to stand 
for 15 minutes and then centrifuged. The plasma was separated and MDA and 
CP analysis were performed immediately.   
Collection of Urine Sample 
 Random mid-stream urine was collected in a test tube and the degree of 
proteinuria was estimated immediately. 
Source of Chemicals 
 All the chemicals used in the study were bought from  HIMEDIA 
chemicals. 
 The dip sticks used for determination of proteinuria were bought from 
BIOLAB diagnostics. 
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STANDARDIZATION OF MALONDIALDEHYDE BY BEUJE JA  & 
AUSTIN  JD METHOD65. 
 Malondialdehyde reacts with thiobarbituric acid forming MDA - TBA2 
adduct with pale pink colour that absorbs light strongly at 532 nm.  
 
 
 
 
Reagents 
 Thiobarbituric acid : 26 mmol / L : Molecular weight of thiobarbituric 
acid  is 144.15.  3747 mg was taken in a volumetric flask. To this deionised 
water was added slowly with continuous stirring. After it was completely 
dissolved the volume was made to 1000 ml by adding deionised water.  
Trichloroacetic Acid (0.92 mol / L) 
153.318 g of TCA was taken in a volumetric flask and dissolved in 0.25 mol/L 
of HCL.The final volume was made to 1000ml by adding 0.25 mol/L of HCL  
Preparation of Standards  
 TMP ( 1, 1, 3,3, Tetramethoxy propane ) was used to prepared standards 
for  malondialdehyde. 
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 The molecular weight of TMP is 164.2. 
 Preparation of Stock 1 : 164.2 mg of TMP was taken in a 1000 ml 
volumetric flask, and made to 1000 ml by adding deionised water. This 
corresponds to 1mmoL/L or 1000 µmol/L 
Stock 2 : 10 ml of stock 1 was  mixed with 90 ml of deionised water. This 
corresponds to 100 µmol/L 
Working standards 
 From stock 2 various concentration of working standards were prepared 
as follows.  
Preparation of various concentration of MDA Standards 
Standard 
Concentration MDA 
in µmol / L 
Volume of Stock 2 in 
ml 
Volume of distilled 
water in ml  
1 
2 
3 
4 
5 
6 
.1 ml 
.2 m1 
.3 ml 
.4 ml 
.5 ml 
.6 ml 
9.9 ml 
9.8 ml 
9.7 ml 
9.6 ml 
9.5 ml 
9.4 ml 
Procedure for Standardization 
 0.5 ml of 1 µ mol/L solution of MDA standard and 0.5 ml of deionised 
water was taken in a test tube. To this 1 ml 0.92 mol/L of TCA was added 
followed by 1 ml of TBA solution. This test tube was kept in a boiling water 
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bath for 15 minutes. After that the tube was taken out and ice cooled. The 
optical density of final product was measured at 532 nm. 
 The same procedure was repeated with various concentrations of MDA 
standards. The standard graph was obtained by plotting the standard 
concentration in X axis and optical density in y axis.    
Table 
Concentration of Standard 
in µ mol / L Optical density 
1 
2 
3 
4 
5 
6 
.010 
.020 
.030 
.040 
.050 
.060 
 
Test procedure 
 Three test tubes were taken and marked blank, standard and test. To 
each test tubes the following reagents were added in order.  
 Blank Standard Test 
Standard  - 0.5 ml - 
Plasma  - - 0.5 ml 
Deionised Water 1 ml 0.5 ml 0.5 ml 
TCA 1 ml 1 ml 1 ml 
TBA 1 ml 1 ml 1 ml 
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   The test tubes were kept in a boiling water bath for 15 minutes. At the 
end the tubes were taken out and cooled in the ice to stop the reaction. Then the 
contents are vortex mixtured for one minute and then centrifuged at 1000 g  for 
10 minutes. The clear pale supernant was collected and read at 532 nm.  
Calculation   
 For 3 µmol/L standard : 1 ml of 3 µmol/L solution contains .003 
µmol/L, from this only .5 ml was used for test.  
           OD.Test  Concentration of Standard 
        OD Standard       Volume of Standard 
           OD.Test   0.00015 
        OD Standard       0.5 
           OD.Test    
        OD Standard    
The results were expressed in  µ mol / L. 
∴ × ×   1000 
∴ × ×   1000 
∴ ×  3 
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STANDARDIZATION OF CERULOPLASMIN  OXIDASE 
ACTIVITY BY SCHOSINKY ET AL METHOD66 
Assay Principle   
 In this method O dianisidine dihydrochloride was used as substrate. This 
substrate was converted to yellowish brown product by ceruloplasmin oxidase 
and oxygen at pH 5. The pH was provided by acetate buffer. Acidification by 
sulfuric acid stops the enzymatic reaction and forms a purplish red solution that 
can be measured at 540 nm.  
Reagents 
 Acetate buffer : - 990 ml of deionised water was taken in a 1000 ml 
volumetric flask. To this 13.608 gm of sodium acetate and 2.6 ml of glacial 
acetic acid was added and then final volume was made to 1000 ml by adding 
deionised water. 
 The pH was measured by pH meter. The final pH of the buffer was 5 
and ionic strength 0.1. 
Sulfuric acid: 9 mol / Ltr 
 125 ml of concentrated H2So4 was taken in measuring jar and 125ml of   
deionised water  was added to make 250ml of 9 mol / Ltr Sulfuric acid. 
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O - dianisidine dihydrochloride : 7.88 mmoL/L 
 250 mg of O - dianisidine dihydrochloride was taken in a 100 ml 
volumetric flask, and deionised water was added slowly until it completely 
dissolved. The final volume was made to 100 ml by adding deionised water. 
This reagent was stored in a brown glass reagent bottle and kept at 400C. 
Procedure 
 Two test tubes were taken. One test tube was marked 5 and another was 
marked 10. To each tube 0.75 ml of acetate buffer and 0.05 ml of plasma was 
pipetted. The tubes were kept in a 30oC water bath. After five minutes 0.2 ml of 
O-dianosidine dihydrochloride was added and the time was noted. Exactly  
after 5 minutes the tube marked 5 was taken out from water bath and 2 ml of 
sulfuric acid reagent was added to stop the reaction. The resulting purplish red 
solution was read at 540nm. After 15 minutes the tube marked 15 was removed 
and the same procedure was repeated.  
The Ceruloplasmin activity in international unit was calculated by  
U / Liter  = Absorbance 1 1x x x 60x1000
Asorptivity t b
      
   Absorbance   
U / Liter  =        ×  100060
b
1
t
1 ×××  
    
Where  
 Absorbance  =     A15   –  A5  
Absorptivity
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 A15 and A5 were the measured absorbances of the "15 minutes and  
5 minutes" solution. 
Absorptivity =    9.6 [molar absorptivity of coloured solution in terms of  
     substrate consumed (µ mol-1 cm-1)]   
 t =   incubation period (10 minutes) 
 b =   optical length (1 cm) 
 60 =  volume correction factor (0.05 ml of plasma was incubated in 
1 ml of reaction mixture which is diluted to 3 ml with 9 molar sulfuric acid) 
 Substituting the values in the above expression 
Activity  = 100060
cm1
1
utesmin10
1
cmmol6.9
)AA(.D.O
11
515 ××××µ
−
−−  
Activity (u / lit) = Absorbance ×  6.25 × 102 
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PROTEINURIA 
Principle  
 This principle in known as protein error of indicator. 
The reactive portion of the stick is coated with the buffered indicator. It 
changes colour in the presence of protein. In dipstick method (AlbustiX – 
BIOLAB diagnostics)67 bromophenol blue buffered to pH3 with citrate, is 
present predominantly in the protonated yellow form. When  protein is added, 
the affinity of the anionic form of the indicator dye for protein cause a shift of 
equilibrium  between anionic and protonated forms of the indicator towards the 
formation of blue anionic species.   
The intensity of the blue colour produced is proportional to the 
concentration of protein present in the urine.  
Procedure 
 The yellow coloured  portion of the dip stick was dipped in the urine and 
then allowed to dry for 30 seconds. After 30 seconds the colour change was 
matched with the colours  given in the colour index.  
 Yellow    - Nil 
 Yellowish green - 1 + ≥ 30 mg 
 Various shades of blue from 2 + to 4 + 
 1 + corresponds to 30 mg / dl 
 2 +   =  100 mg / dl 
 3 + =  300 mg / dl 
 4+ =  1000 mg/ dl    
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RESULTS 
 A total number of 90 subjects were included in the study. They were 
divided into three groups. 
Group 1 : Unpregnant normotensive women N = 30. 
Group 2 : Uncomplicated normotensive pregnancies N = 30. 
Group 3 : Preeclampsia pregnancies N = 30 
The three groups were matched for age and parity. 
Statistical Analysis 
 In all the groups one way ANOVA was used to calculate the P valve. 
 Multiple range test by Tukey - HSD procedure was employed to identify the 
significant groups at 5% level. 
 Pearson correlation analysis was carried out to assure the relationship 
between MDA and CP in each study group. 
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Table 1 
Comparison of mean levels of plasma MDA between non pregnant     
(group 1), un complicated pregnancy (group 2),and preeclampsia(group 3) 
Group N MDA levels  Mean ± SD in µ mol / L p 
Significant 
groups at 
5% Level 
1 30 2.5 ± 0.3  
2 30 3.9 ± 0.3 2 vs 1 
3 30 4.7 ± 0.3 
< 0.001 
3 vs 2 
 
The mean level of plasma MDA of group 2 was compared with the 
mean level of plasma MDA of group 1. The mean level of plasma MDA was 
significantly higher in group 2 than in group 1 (p<0.001) 
The mean level of plasma MDA of group 3 was compared with the 
mean level of plasma MDA of group 2. The mean level of plasma MDA was 
significantly higher in group 3 than in group 2 (p<0.001). 
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Table 2 
Comparison of mean levels of plasma CP activity between non pregnant     
(group 1), un complicated pregnancy (group 2),and preeclampsia(group 3)  
 
Group N 
CP activity Levels  
Mean ± SD (U/L) 
p 
Significant 
groups at 
5% Level 
1 30 156.9 ± 12.6  
2 30 337.8 ± 26.5 2 vs 1 
3 30 269.9 ± 22.8 
< 0.001 
3 vs 2 
 
The mean level of plasma CP activity of group 2 was compared with the 
mean level of plasma CP activity of group 1. The mean level of plasma CP 
activity was significantly higher in group 2 than in group 1 (p<0.001) 
The mean level of plasma CP activity of group 3 was compared with the 
mean level of plasma CP activity of group 2. The mean level of plasma CP 
activity was significantly lower in group 3 than in group 2 (p<0.001) 
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Table 3 
Comparison of mean levels of MDA / CP ratios between non pregnant     
(group 1), un complicated pregnancy (group 2),and preeclampsia(group 3) 
Group N MDA / CP ratio  Mean ± SD  p 
Significant 
groups at 
5% Level 
1 30 0.016 ± 0.002  
2 30 0.011 ± 0.001 2 vs 1 
3 30 0.017 ± 0.001 
< 0.001 
3 vs 2 
 
 The mean ratio of   MDA / CP of group 2 was compared with the mean 
ratio of MDA / CP of group 1. The mean ratio of MDA / CP in group 2  was 
significantly lower in group 2 than in group 1 (p<0.001) 
The mean ratio of   MDA / CP of  group 3 was compared with the mean 
ratio of  MDA / CP of group 2. The mean ratio of MDA / CP is significantly 
higher in group 3 than in group 2 (p<0.001) 
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Table 4 
Parity wise comparison (parity 0) of  mean levels of plasma  MDA  
between non pregnant (group 1), un complicated pregnancy (group 2),and 
preeclampsia(group 3) 
 
 
Group N 
MDA levels 
Mean ± SD 
             µ mol / L 
p 
Significant 
groups at 
5% Level 
1 5 2.28 ± 0.19   
2 16 3.87 ± 0.25 2 vs 1 
3 15 4.69 ± 0.28 
< 0.000 
3 vs 2 
 
 The mean level of plasma MDA of group 2 was compared with the 
mean level of plasma MDA of group 1. The mean level of plasma MDA was 
significantly higher in group 2 than in group 1 (p<0.000) 
The mean level of plasma MDA of group 3 was compared with the 
mean level of plasma MDA of group 2. The mean level of plasma MDA was 
significantly higher in group 3 than in group 2 (p<0.000) 
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Table 5 
Parity wise comparison (parity 0) of  mean levels of plasma  CP activity 
between non pregnant (group 1), un complicated pregnancy (group 2),and 
preeclampsia(group 3) 
 
Group N 
CP activity Levels 
Mean ± SD  
(U/L) 
p 
Significant 
groups at 
5% Level 
1 5 160.25 ± 10  
2 16 336.90 ± 20 2 vs 1 
3 15 269.49 ± 25 
< 0.000 
3 vs 2 
 
 The mean level of plasma CP activity of group 2 was compared with the 
mean level of plasma CP activity of group 1. The mean level of plasma CP 
activity was significantly higher in group 2 than in group 1 (p<0.000) 
The mean level of plasma CP activity of group 3 was compared with the 
mean level of plasma CP activity of group 2. The mean level of plasma CP 
activity was significantly lower in group 3 than in group 2 (p<0.000) 
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Table 6 
Parity wise comparison (parity 0) of  mean levels of  MDA / CP ratio 
between non pregnant (group 1), un complicated pregnancy (group 2),and 
preeclampsia(group 3) 
Group N 
MDA / CP Ratio 
Mean + SD  
p 
Significant 
groups at 
5% Level 
1 6 .0168  ±  .003  
2 16 .0111 ±  .0010 2 vs 1 
3 15 .0161  ±  .008 
< 0.000 
3 vs 2 
 
 The mean ratio of   MDA / CP of  group 2 was compared with the mean 
ratio of  MDA / CP of group 1. The mean ratio of MDA / CP in group 2  was 
significantly lower in group 2 than in group 1 (p<0.000) 
The mean ratio of   MDA / CP of  group 3 was compared with the mean 
ratio of  MDA / CP of group 2. The mean ratio of MDA / CP is significantly 
higher in group 3 than in group 2 (p<0.000) 
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Table 7 
Parity wise comparison (parity 1) of  mean levels of plasma  MDA  
between non pregnant (group 1), un complicated pregnancy (group 2),and 
preeclampsia(group 3) 
 
Group N 
MDA levels 
Mean ± SD 
  (µ mol / L) 
p 
Significant 
groups at 
5% Level 
1 18 2.50  ±  0.30  
2 9 3.95 ± 0.30 2 vs 1 
3 10 4.63 ± 0.26 
< 0.000 
3 vs 2 
 
 The mean level of plasma MDA of group 2 was compared with the 
mean level of plasma MDA of group 1. The mean level of plasma MDA was 
significantly higher in group 2 than in group 1 (p<0.000) 
The mean level of plasma MDA of group 3 was compared with the 
mean level of plasma MDA of group 2. The mean level of plasma MDA was 
significantly higher in group 3 than in group 2 (p<0.000) 
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Table 8 
Parity wise comparison (parity 1) of  mean levels of plasma  CP activity 
between non pregnant (group 1), un complicated pregnancy (group 2),and 
preeclampsia(group 3) 
 
Group N 
CP activity Levels  
Mean ± SD  
(U/L) 
p 
Significant 
groups at 
5% Level 
1 18 154.49  ±  12.72  
2 9 341.68  ±  27.53 2 vs 1 
3 10 269.18 ± 22.7 
< 0.000 
3 vs 2 
 
 The mean level of plasma CP activity of group 2 was compared with the 
mean level of plasma CP activity of group 1. The mean level of plasma CP 
activity was significantly higher in group 2 than in group 1 (p<0.000) 
The mean level of plasma CP activity of group 3 was compared with the 
mean level of plasma CP activity of group 2. The mean level of plasma CP 
activity was significantly lower in group 3 than in group 2 (p<0.000) 
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Table 9 
Parity wise comparison (parity 1) of  mean levels of  MDA / CP ratio 
between non pregnant (group 1), un complicated pregnancy (group 2),and 
preeclampsia(group 3) 
 
 
Group N 
MDA / CP Ratio 
Mean + SD 
p 
Significant 
Groups at  
5% level 
1 18 .0164 ± .0023  
2 9 .0112 ± .0011 2 vs 1 
3 10 .0168 ± .0012 
< 0.000 
3 vs 2 
 
 The mean ratio of   MDA / CP of  group 2 was compared with the mean 
ratio of  MDA / CP of group 1. The mean ratio of MDA / CP in group 2  was 
significantly lower in group 2 than in group 1 (p<0.000) 
The mean ratio of   MDA / CP of  group 3 was compared with the mean 
ratio of  MDA / CP of group 2. The mean ratio of MDA / CP is significantly 
higher in group 3 than in group 2 (p<0.000) 
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Table 10 
Parity wise comparison (parity 2) of  mean levels of plasma  MDA  
between non pregnant (group 1), un complicated pregnancy (group 2),and 
preeclampsia(group 3) 
Group N 
MDA levels 
Mean ± SD 
  µ mol / L 
p 
Significant 
Groups at  
5% level 
1 7 2.65 ± .21  
2 5 3.94 ± .28 2 vs 1 
3 5 4.64 ± .25 
< 0.000 
3 vs 2 
 
 The mean level of plasma MDA of group 2 was compared with the 
mean level of plasma MDA of group 1. The mean level of plasma MDA was 
significantly higher in group 2 than in group 1 (p<0.000) 
The mean level of plasma MDA of group 3 was compared with the 
mean level of plasma MDA of group 2. The mean level of plasma MDA was 
significantly higher in group 3 than group 2 (p<0.000) 
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Table 11 
Parity (P2) wise Comparison of Mean Ceruloplasmin activity between 
Control (Group1), Uncomplicated Pregnancy (Group 2) and  
Preeclampsia (Group 3) 
 
Group N 
CP activity Levels  
Mean ±  SD 
(U/L)  
p 
Significant 
Groups at 
5% level 
1 7 160.53 ± 13.83  
2 5 333.62  ±  27.47 2vs1 
3 5 272.25  ±  20.22 
< 0.000 
3vs2 
 
The mean level of plasma CP activity of group 2 was compared with the 
mean level of plasma CP activity of group 1. The mean level of plasma CP 
activity was significantly higher in group 2 than in group 1 (p<0.000) 
The mean level of plasma CP activity of group 3 was compared with the 
mean level of plasma CP activity of group 2. The mean level of plasma CP 
activity was significantly lower in group 3 than in group 2 (p<0.000) 
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Table 12  
Parity wise comparison (parity 2) of  mean levels of  MDA / CP ratio 
between non pregnant (group 1), un complicated pregnancy (group 2),and 
preeclampsia(group 3) 
 
Group N 
MDA /C P ratio 
Mean + SD 
p 
Significant 
Groups at 
5% level 
1 7 .0161 ± .0018  
2 5 .0114  ± .0013 2 vs 1 
3 5 .0166  ±  .005 
< 0.000 
3 vs 2 
 
The mean ratio of   MDA / CP of  group 2 was compared with the mean 
ratio of  MDA / CP of group 1. The mean ratio of MDA / CP in group 2  was 
significantly lower in group 2 than in group 1 (p<0.000) 
The mean ratio of   MDA / CP of  group 3 was compared with the mean 
ratio of  MDA / CP of group 2. The mean ratio of MDA / CP is significantly 
higher in group 3 than in group 2 (p<0.000) 
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Table 13 
Correlation between MDA levels and CP activity in plasma from control, 
uncomplicated pregnancy and preeclampsic  group 
 
Groups r p 
Non Pregnant Control 0.04 0.41 
Uncomplicated pregnancy 0.24 0.10 
Pre eclampsia 0.77 0.0001 
 
There was no correlation between MDA and CP in control and normal 
pregnant group.  There was correlation between MDA and CP in preeclampsic 
group.(p < 0.0001) 
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Table 14   
Parity wise comparison of mean levels of plasma MDA  in  
non pregnant group 
(Group 1) 
Parity N MDA levels Mean ± SD in µ mol / L p-value 
0 5 2.28  ± 0.19 
1 18 2.56 ± 0.30 
2 7 2.65 ± 0.21 
0.0774 
 The mean levels of plasma MDA of various parities in group 1 were 
compared to each other [P0 vs P1;  P1 vs P2;  P2  vs  P1]. No two groups were 
significantly different at the 0.050 level [p= 0.0774]. 
Table 15  
Parity wise comparison of mean levels of plasma CP activity in non 
pregnant  group 
 (Group 1) 
 
Parity N CP activity levels  Mean ± SD (U/L) p-value 
0 5 160.25 ± 10.73 
1 18 154.49 ± 12.72 
2 7 160.53 ± 13.85 
0.468 
 The mean levels of plasma CP activity of various parities in group  
1 were compared to each other [P0 vs P1;  P1 vs P2;  P2  vs  P1]. No two groups 
were significantly different at the 0.050 level [p = 0.468]. 
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Table 16 
Parity wise comparison of mean ratios of MDA / CP in   
non pregnant Control group 
(Group 1) 
 
Parity N 
MDA / CP ratio 
Mean ± SD 
p-value 
0 5 0.0168  ±  0.001 
1 18 0.0164  ±  0.002 
2 7 0.0161 ±  0.001 
0.0632 
 The mean ratio of  MDA / CP ratios of various parities of group 1 were 
compared to each other [P0 vs P1;  P1 vs P2;  P2 vs  P1]. No two groups were 
significantly different at the 0.050 level [p = 0.0632]. 
Table 17  
Parity wise comparison of mean levels of plasma MDA  in un  
complicated pregnancies group 
 (Group 2) 
 
Parity N MDA levels  Mean ± SD in µ mol / L p-value 
0 16 3.91 ± 0.26 
1 9 3.95 ± 0.30 
2 5 3.94 ± 0.28 
0.769 
 The mean levels of plasma MDA of various parities in group 2 were 
compared to each other [P0 vs P1;  P1 vs P2;  P2  vs  P1]. No two groups were 
significantly different at the 0.050 level [p = 0.769]. 
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Table 18   
Parity wise comparison of mean levels of plasma CP activity in un 
complicated pregnancies 
 
 (Group 2) 
Parity N CP activity levels  Mean ± SD (U/L) p-value 
0 16 336.99 ± 27.11 
1 9 341.68 ± 27.53 
2 5 333.62 ± 27.47 
0.855 
 The mean levels of plasma CP activity of various parities in group 2 
were compared to each other [P0 vs P1;  P1 vs P2;  P2  vs  P1]. No two groups 
were significantly different at the 0.050 level [p = 0.855]. 
Table 19  
Parity wise comparison of mean ratios of MDA / CP  in  un complicated 
pregnancies 
 (Group 2) 
Parity N 
MDA / CP ratio 
Mean + SD 
p-value 
0 16 0.0111 ± 0.0010 
1 9 0.0112 ± 0.0011 
2 5 0.0114 ± 0.0013 
0.818 
 The mean ratio of  MDA / CP ratios of various parities of group 2 were 
compared to each other [P0 vs P1;  P1 vs P2;  P2 vs  P1]. No two groups were 
significantly different at the 0.050 level [p = 0.818]. 
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Table 20  
Parity wise comparison of mean levels of plasma MDA  in preeclampsic 
pregnancies 
 (Group 3) 
 
Parity N 
MDA levels  
Mean ± SD in  
µ mol / L 
p-value 
0 15 4.69 ± 0.28 
1 10 4.63 ± 0.26 
2 5 4.64 ± 0.25 
0.849 
 The mean levels of plasma MDA of various parities in group 3 were 
compared to each other [P0 vs P1;  P1 vs P2;  P2  vs  P1]. No two groups were 
significantly different at the 0.050 level [p = 0.849]. 
Table 21  
Parity wise comparison of mean levels of plasma CP activity in 
preeclampsic  group 
 (Group 3) 
Parity N CP activity levels  Mean ± SD (U/L) p-value 
0 15 269.49 ± 25.01 
1 10 269.18 ± 22.72 
2 5 272.25 ± 20.22 
0.969 
 The mean levels of plasma CP activity of various parities in group 3 
were compared to each other [P0 vs P1;  P1 vs P2;  P2  vs  P1]. No two groups 
were significantly different at the 0.050 level [p = 0.969]. 
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Table 22  
Parity wise comparison of mean ratios of MDA / CP  in   
preeclampisic pregnancies 
(Group 3) 
 
Parity N 
MDA / CP ratio 
Mean + SD 
p-value 
0 15 0.0160 ± 0.0008 
1 10 0.0168 ± 0.0012 
2 5 0.0166 ± 0.0005 
0.583 
 
 The mean ratio of  MDA / CP  of various parities of group 3 were 
compared to each other [P0 vs P1;  P1 vs P2;  P2 vs  P1]. No two groups were 
significantly different at the 0.050 level [p = 0.583]. 
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DISCUSSION 
 The etiology and pathogenesis of pregnancy syndrome preeclampsia 
remain poorly understood. The diverse manifestation of preeclampsia including 
altered vascular reactivity, vasospasm are derived from pathological changes 
within the maternal vascular endothelium. 
 The present study was designed to find out the role of oxidative stress in 
pathogenesis of preeclampsia. Oxidative stress is an imbalance favouring 
oxidant over antioxidant system. 
 Hubel, C.A. reported that lipid peroxidation products  may mediate 
disturbance of maternal vascular endothelium. He also reported decreased 
levels of ceruloplasmin in preeclampsic pregnancies. 
 Atamer, et al evaluated the plasma MDA and CP level in 25 non 
pregnant and 25 healthy pregnant women and reported the increased level of 
MDA and CP in pregnant women compared to non pregnant women. 
(p<0.001)68 
 In this study increased  MDA and CP activity were found  in 
uncomplicated normotensive pregnancy group compared to normotensive non 
pregnant control group (p < 0.001). 
 The ratio of MDA/ CP was decreased in normotensive pregnancy group 
compared to normotensive nonpregnant group (p < 0.001). This indicates that 
oxidative stress does not occur in group 2. Results obtained indicate increased 
ceruloplasmin level of maternal plasma is possibly due to a compensatory 
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response to increased lipid peroxidation in normal pregnancy. This antioxidant 
defence protects the cells against oxidative damage. 
 Akshoy, H et al., evaluated MDA and ceruloplamin level in 21 
normotensive pregnancies and 21 preeclampsic pregnancies. They reported 
higher level of MDA and lower level of ceruloplasmin activity in preeclampsic 
pregnancies compared to normotensive pregnancies69. 
 The present study shows increased MDA levels and decreased CP 
activity in preeclampsic pregancies compared to normotensive pregnancies     
(p < 0.001) 
 Increased MDA/ CP ratio was observed in preeclampsic group 
compared to normotensive pregnancies.(p<0.001) 
 This increased MDA/ CP ratio (p<0.001) in preeclampsic group implies 
an impaired oxidant and antioxidant balance in favour of oxidants and can be 
defined as oxidative stress. 
 H. Gurer Orhan et al investigated 12 normotensive non pregnant  
control, 12 uncomplicated normotensive pregnancies and 7 preeclampsic 
pregnancies. They observed correlation between MDA and CP activity in 
preeclampsic group70. 
 In the present study no correlation was observed between MDA & CP in 
group 1 and group 2. There was correlation between MDA and CP in 
preeclampsic group (p < 0.001) which proves the presence of protection against 
oxidative stress. 
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CONCLUSION 
Hydroxyl and alkoxyl radicals are generated during lipid peroxidation. 
MDA, HNE and Isoprostanes are produced during the decomposition of lipid 
hydroperoxides. All these products are probably the cause of the pathogenesis 
of damage to vascular endothelium. 
The increased prooxidant activity is augmented by decreased levels of 
many intra and extra cellular antioxidants. Such a role of oxidative stress as a 
factor for pathogenesis of preeclampsia can be postulated as there are reports of 
decreased level of many anti-oxidants like superoxide dismutase, glutathione, 
vitamin C, vitamin E and ceruloplasmin in preeclampsia. 
The present study has found an increased oxidative stress as shown by 
increased plasma MDA, decreased plasma CP activity and increased MDA / 
CP ratio in patient having preeclampsia. 
Oxidative stress may be the point at which multiple factors converge 
resulting in endothelial dysfunction and consequent clinical manifestation of 
preeclampsia. From this study it is concluded that oxidative stress is one of the 
major factors in the pathogenesis of preeclampsia. 
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LIST OF ABBREVIATIONS USED 
 
MDA : Malondialdehyde 
CP : Ceruloplasmin 
BP : Blood Pressure 
mmHg : Millimeter mercury 
LDH : Lactate dehydrogenase 
GFR : Glomerular filtration rate 
FFA : Free fatty acid 
TGL : Triglycerides 
LDL : Low density lipoprotein 
HDL : High density lipoprotein 
OHy : Hydroxyl radical 
RO2y : Peroxyl rdical 
ROy : Alkoxyl radical 
O2y- : Superoxide radical 
Fe2+ : Ferrous ion 
Fe3+ : Ferric ion 
H2O2 : Hydrogen peroxide 
ROOH : Lipid hydroperoxide 
PUFA : Polyunsaturated Fatty acid 
Ry : Carbon centered radical 
Cu+ : Cuprous ion 
CU2+ : Cupric ion 
DNA : De oxy ribo nucleic acid 
GS – SG : Oxidized Glutathione 
GSH : Reduced glutathione 
NADPH : Nicotinamide adenine di nucleotide phosphate reduced 
NADP : Nicotinamide adenine di nucleotide phosphate 
HMP : Hexose Mono Phosphate 
NADH : Nicotinamide adenine di nucleotide reduced 
NAD : Nicotinamide adenine di nucleotide 
Vit. E - Oy : Tocopheroxyl rdical 
EDTA : Ethylene diamine tetra acetic acid 
TBA : Thiobarbituric acid 
TCA : Trichloroacetic acid 
Hcl : Hydrochloric acid 
O.D. : Optical density 
H2SO4 : Sulfuric acid 
µmol : Micromole 
mmol : millimole 
U/L : Units per litre 
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The mean level of plasma MDA is found to increase in preeclampsia 
(Group 3) when compared to uncomplicated pregnancy (Group 2), showing the 
presence of more  oxidative stress in preeclampsia. 
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Group 2 shows increased mean level of plasma ceruloplasmin activity proving 
the protective function of ceruloplasmin on oxidative stress. 
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PROFORMA 
 
 
GROUP 1  
 
Name  :  Age :  Marital Status : 
 
Parity  :  
 
Past History  : Hypertension 
    Diabetes Mellitus 
    Tuberculosis 
    Other Systemic Disorders 
 
General Examination : BP : 
     PR : 
     CVS : 
     RS : 
 
Investigations :  Urine for Albumin 
     M.D.A.: 
     C.P. : 
 
GROUP 2 & 3 : 
 
Name  :   Age  : 
IP / OP  NO. : 
Obstetric formula: Gravida / Para   Gestational age : 
Present history : LMP 
    EDD 
Past History : Hypertension 
    Diabetes Mellitus 
    Tuberculosis 
    Infection 
    Other systemic disorders 
General Examination : BP :  PR: 
     CVS :  RS : 
INVESTIGATIONS : 
Haemoglobin 
Urine for albumin 
M.D.A. 
C.P. 
